C5B7 (ATCC® CRL-8753)

Organism: Homo sapiens, human  /  Cell Type: B lymphocyte; Epstein-Barr virus (EBV) transforme  / 

Organism Homo sapiens, human
Cell Type B lymphocyte; Epstein-Barr virus (EBV) transforme
Product Format frozen
Morphology lymphoblast
Culture Properties suspension
Biosafety Level 2 Cells Contain HERPESVIRUS
Applications
The antibody is specific for the lipopolysaccharide of the Fisher immunotype 1 of P. aeruginosa.
Storage Conditions liquid nitrogen vapor phase
Derivation
B cells obtained from a patient with cystic fibrosis (whose serum contained above normal titer to P. aeruginosa) were transformed with Epstein-Barr virus (EBV).
Clinical Data
B cells obtained from a patient with cystic fibrosis (whose serum contained above normal titer to P. aeruginosa) were transformed with Epstein-Barr virus (EBV).
Genes Expressed
immunoglobulin; monoclonal antibody; against Pseudomonas aeruginosa lipopolysaccharide (LPS) of Fisher immunotype 1 (IATS type 6)
Cellular Products
immunoglobulin; monoclonal antibody; against Pseudomonas aeruginosa lipopolysaccharide (LPS) of Fisher immunotype 1 (IATS type 6)
Comments
B cells obtained from a patient with cystic fibrosis (whose serum contained above normal titer to P. aeruginosa) were transformed with Epstein-Barr virus (EBV).
The antibody is specific for the lipopolysaccharide of the Fisher immunotype 1 of P. aeruginosa.
Complete Growth Medium Iscove's modified Dulbecco's medium with 2 mM L-glutamine, 85%; heat-inactivated fetal bovine serum, 15%
Subculturing
Medium Renewal: Every 3 to 4 days
Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml.
Cryopreservation
Freeze medium: complete growth medium, 95%; DMSO, 5%
Culture Conditions
Temperature: 37.0°C
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Isotype IgM
Population Doubling Time 24 to 36 hrs
Name of Depositor Miles Inc., Genetics Systems Corporation
References

Siadak AW, Lostrom ME. Human monoclonal antibodies to serotypic lipopolysaccharide determinants on Gram-negative bacteria and their production. US Patent 4,834,975 dated May 30 1989

Basic Documentation
References

Siadak AW, Lostrom ME. Human monoclonal antibodies to serotypic lipopolysaccharide determinants on Gram-negative bacteria and their production. US Patent 4,834,975 dated May 30 1989